Nereida Parada, MD
Pulmonary Disease · New Orleans, LANPI 1376636175
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (56.0%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 23 manufacturers reported payments, led by Sanofi at 56.2% of the total. Reporting peaked in 2023 at $6,062 and has fallen 72.7% since, to $1,653 in 2025.
Across 168 payments — averaging $62.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$6K
- GSK$1K
- AstraZeneca$1K
- Regeneron Healthcare Solutions, Inc.$611
- Philips North America LLC$571
- Astrazeneca UK Limited$146
- plus $917 from 17 others
Across 13 payments — averaging $21,419 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$278K
What the payments were for
- Consulting fees$4,20840%
- Travel & lodging$3774%
- Food & beverage$5,87756%
- Gifts$300%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 29 | $5,901 |
| GSK | 50 | $1,301 |
| AstraZeneca | 18 | $1,045 |
| Regeneron Healthcare Solutions, Inc. | 17 | $611 |
| Philips North America LLC | 11 | $571 |
| Astrazeneca UK Limited | 2 | $146 |
| Boehringer Ingelheim | 3 | $140 |
| Mylan Specialty L.p. | 5 | $110 |
| Amgen | 5 | $104 |
| Grifols USA, LLC | 5 | $97 |
| Insmed, Inc. | 5 | $93 |
| Sunovion Pharmaceuticals Inc. | 4 | $66 |
| Genentech USA, Inc. | 2 | $55 |
| Viatris Specialty LLC | 2 | $40 |
| Novartis | 2 | $40 |
| Merz North America, Inc. | 1 | $30 |
| UCB, Inc. | 1 | $23 |
| United Therapeutics Corporation | 1 | $22 |
| Electromed, Inc. | 1 | $22 |
| Merck | 1 | $21 |
| Alcresta Therapeutics, Inc. | 1 | $21 |
| AbbVie | 1 | $17 |
| Gilead | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$10,492 in reported general payments places this provider in the 70th percentile of 189 pulmonary disease providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent PenDupilumab | 84 | $316,777 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 192 | $150,161 |
| TezspireTezepelumab-Ekko | 24 | $107,052 |
| Fasenra PenBenralizumab | 16 | $91,546 |
| Spiriva RespimatTiotropium Bromide | 88 | $57,856 |
| NucalaMepolizumab | 11 | $40,920 |
| XolairOmalizumab | 18 | $35,874 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 50 | $34,175 |
| SymbicortBudesonide/Formoterol Fumarate | 63 | $19,673 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 30 | $16,449 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 14 | $11,562 |
| Qvar RedihalerBeclomethasone Dipropionate | 35 | $10,787 |
| DuleraMometasone/Formoterol | 12 | $6,995 |
| Incruse ElliptaUmeclidinium Bromide | 11 | $6,634 |
| Arnuity ElliptaFluticasone Furoate | 23 | $6,587 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Nucala, Incruse Ellipta, Arnuity Ellipta | $1,301 | $204,302237 claims |
| AstraZenecaTezspire, Breztri Aerosphere, Symbicort | $1,045 | $160,900137 claims |
| Boehringer IngelheimSpiriva Respimat, Stiolto Respimat, Combivent Respimat | $140 | $85,868132 claims |
| MerckDulera | $21 | $6,99512 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 189 pulmonary disease providers in Louisiana.
Other pulmonary disease in New Orleans
- Joseph LaskyNew Orleans$447K
- Ramsy AbdelghaniNew Orleans$308K
- Juzar AliNew Orleans$216K
- Nicole LapinelNew Orleans$140K
- Courtney ShappleyNew Orleans$66K
- Susan GunnNew Orleans$28K
- David PattenNew Orleans$12K
- Yasin KhanNew Orleans$12K
- Ross KlingsbergNew Orleans$11K
- Leonard GladeNew Orleans$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.